Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05456243 · ClinicalTrials.gov registry record · Phase 1
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
A Phase 1 study of Kidney Transplant, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05456243 is a Phase 1 study of Kidney Transplant that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 12 participants, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05456243, a Phase 1 study of Kidney Transplant, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the transplanted kidney and treat rejection.
Conditions Studied
Interventions
- BIOLOGICAL Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)
- BIOLOGICAL High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05456243
The ClinicalTrials.gov registry entry for NCT05456243 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant appearing as the primary indexed condition, and to 2 interventions - of which Low dose adipose tissue derived mesenchymal stromal cells (A-MSC) is the first listed.
NCT05456243 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05456243 about?
NCT05456243 is a clinical study titled "Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients". This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the transplanted kidney and treat rejection.
What is the current status of trial NCT05456243?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-01-30. Estimated completion is 2026-04.
What conditions does trial NCT05456243 study?
This clinical trial studies the following conditions: Kidney Transplant.
What interventions are being tested in trial NCT05456243?
The interventions under investigation include: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC) (BIOLOGICAL), High dose adipose tissue derived mesenchymal stromal cells (A-MSC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05456243?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05456243 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
RECRUITING · Phase 1
-
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
RECRUITING · Phase 1
-
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
ACTIVE NOT RECRUITING · Phase 1
-
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
Social Support Counseling Intervention for Kidney Transplant Candidates
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.